Hedy Kindler to Paclitaxel
This is a "connection" page, showing publications Hedy Kindler has written about Paclitaxel.
Connection Strength
0.339
-
5-FU, Irinotecan, Nab-Paclitaxel in Gastrointestinal Cancers-Response. Clin Cancer Res. 2020 07 15; 26(14):3890.
Score: 0.164
-
Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B. Cancer. 2003 May 15; 97(10):2480-6.
Score: 0.050
-
Genome-wide association studies of survival in 1520 cancer patients treated with bevacizumab-containing regimens. Int J Cancer. 2022 01 15; 150(2):279-289.
Score: 0.045
-
Clinical Assessment of 5-Fluorouracil/Leucovorin, Nab-Paclitaxel, and Irinotecan (FOLFIRABRAX) in Untreated Patients with Gastrointestinal Cancer Using UGT1A1 Genotype-Guided Dosing. Clin Cancer Res. 2020 01 01; 26(1):18-24.
Score: 0.039
-
Paclitaxel and carboplatin in early phase studies: Roswell Park Cancer Institute experience in the subset of patients with lung cancer. Semin Oncol. 1997 Aug; 24(4 Suppl 12):S12-138-S12-143.
Score: 0.033
-
The clinical development of paclitaxel and the paclitaxel/carboplatin combination. Eur J Cancer. 1998 Sep; 34(10):1543-8.
Score: 0.009